1. Articles in category: Cells and Stem Cells

    1-24 of 276 1 2 3 4 ... 10 11 12 »
    1. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jul 18;:

      Authors: Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J, Bronner ME

      Read Full Article
      Mentions: MYCN
    2. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    3. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Br J Cancer. 2018 Jul 11;:

      Authors: Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T

      Read Full Article
      Mentions: GPOH Chemotherapy
    4. EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma – the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targe

      Read Full Article
    5. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    6. Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Pediatr Transplant. 2018 Jun 19;:e13240

      Authors: Liu APY, Lee PPW, Kwok JSY, Leung RYY, Chiang AKS, Ha SY, Cheuk DKL, Chan GCF

      Abstract Relapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity.

      Read Full Article
    7. New method to preserve boy cancer patient fertility being developed

      New method to preserve boy cancer patient fertility being developed

      Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center researchers in Beer-Sheva, Israel are developing a cell culture system that for the first time can change testicular stem cells into sperm-like cells that may enable future fertility for boys with prepubertal cancer.

      Read Full Article
      Mentions: Genetics
    8. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    9. Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      J Cancer Stem Cell Res. 2017;5:

      Authors: Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ

      Abstract The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some other non-hematopoietic tissues including several solid tumor cells and proposed candidates for cancer stem cells. This is an important concern, because recombinant erythropoietin (EPO) is frequently employed in cancer patients as a drug to ameliorate anemia related to chemo/radiotherapy. In our studies, we employed three human neuroblastoma ...

      Read Full Article
      Mentions: Radiotherapy
    10. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      Am J Surg Pathol. 2018 May 22;:

      Authors: Xie Y, Xu H, Fang F, Li Z, Zhou H, Pan J, Guo W, Zhu X, Wang J, Wu Y

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in children with contrasting outcomes. Precise risk assessment contributes to prognosis prediction, which is critical for treatment strategy decisions.

      Read Full Article
      Mentions: Treatment
    11. Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Surgery. 2018 May 09;:

      Authors: Subramanian C, White PT, Kuai R, Kalidindi A, Castle VP, Moon JJ, Timmermann BN, Schwendeman A, Cohen MS

      Read Full Article
      Mentions: Surgery
    12. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    13. Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Pediatr Blood Cancer. 2018 Apr 25;:e27110

      Authors: Johnston DL, Murray S, Irwin MS, Doyle J, Schechter T

      Abstract Opsoclonus, myoclonus, ataxia syndrome (OMA) is a severe neurologic disorder often associated with neuroblastoma. It is challenging to treat and can have long-term neurologic sequelae.

      Read Full Article
      Mentions: Refractory
    14. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.

      High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.

      Bone Marrow Transplant. 2018 Apr 19;:

      Authors: Jodele S, Dandoy CE, Myers K, Wallace G, Lane A, Teusink-Cross A, Weiss B, Davies SM

      Read Full Article
      Mentions: Bone Marrow
    15. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      J Pediatr Hematol Oncol. 2018 Apr 10;:

      Authors: Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS

      Read Full Article
    16. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    17. Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      J Extra Corpor Technol. 2018 Mar;50(1):61-64

      Authors: Williams FZ, Vats A, Cash T, Fortenberry JD

      Abstract Respiratory failure associated with hematopoietic stem cell transplantation (HSCT) has been considered a contraindication for use of extracorporeal membrane oxygenation (ECMO) at many centers.

      Read Full Article
    18. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.

      The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.

      Gene. 2018 Jan 21;:

      Authors: Yousefnia S, Momenzadeh S, Forootan FS, Ghaedi K, Esfahani MHN

      Abstract Peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear receptor superfamily of PPARs (PPARα, PPARβ/δ, PPARγ).

      Read Full Article
    19. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK

      Read Full Article
      Mentions: Refractory NANT MYCN
    1-24 of 276 1 2 3 4 ... 10 11 12 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles